Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer

Cancer Letters

Volumn 308, Issue 1, 2011, Pages 43-53

  Wu, Jing ^a   Omene, Coral ^a   Karkoszka, Jerzy ^a   Bosland, Maarten ^a   Eckard, Jonathan ^a   Klein, Catherine B ^a   Frenkel, Krystyna ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Apoptosis; Breast cancer; CAPE; Cell cycle

Indexed keywords

CAFFEIC ACID PHENETHYL ESTER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROPOLIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CELL CYCLE ARREST; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HONEYBEE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BEES; BREAST NEOPLASMS; CAFFEIC ACIDS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PHENYLETHYL ALCOHOL; PROPOLIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

APIS MELLIFERA;

EID: 79958157538     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.04.012     Document Type: Article

References (64)

1. Nutritional Business Journal (NBJ), Integrative Medicine Report, 2009.
2. Boon H., Brown J.B., Gavin A., Kennard M.A., Stewart M. Breast cancer survivors' perceptions of complementary/alternative medicine (CAM): making the decision to use or not to use. Qual. Health Res. 1999, 9:639.
3. Institute for Health and Healing at California Pacific Medical Center, March 2002.
4. DiGianni L.M., Garber J.E., Winer E.P. Complementary and alternative medicine use among women with breast cancer. J. Clin. Oncol. 2002, 20(18):34S-38S.
5. Crocetti E., Crotti N., Feltrin A., Ponton P., Geddes M., Buiatti E. The use of complementary therapies by breast cancer patients attending conventional treatment. Eur. J. Cancer 1998, 34:324-328.
6. Sparber A., Bauer L., Curt G., Eisenberg D., Levin T., Parks S., Steinberg S.M., Wootton J. Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol. Nurse Forum 2000, 27:623-630.
7. Richardson M.A., Sanders T., Palmer J.L., Greisinger A., Singletary S.E. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J. Clin. Oncol. 2000, 18:2505-2514.
8. Morris K., Johnson N., Homer L., Walts D. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am. J. Surg. 2000, 179:407-411.
9. Lotfy M., Badra G., Burham W., Alenzi F.Q. Combined use of honey, bee propolis and myrrh in healing a deep, infected wound in a patient with diabetes mellitus. Br. J. Biomed. Sci. 2006, 63(4):171-173.
10. Castaldo S., Capasso F. Propolis, an old remedy used in modern medicine. Fitoterapia 2002, 73(Suppl. 1):S1-S6.
11. Ansorge S., Reinhold D., Lendeckel U. Propolis and some of its constituents down-regulate DNA synthesis and inflammatory cytokine production but induce TGF-beta 1 production of human immune cells. Z. Naturforsch. 2003, 58:580-589.
12. Burdock G.A. Review of the biological properties and toxicity of bee propolis (propolis). Food Chem. Toxicol. 1998, 36(4):347-363.
13. Grunberger D., Banerjee R., Eisinger K., Oltz E.M., Efros L., Caldwell M., Estevez V., Nakanishi K. Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis. Experientia 1988, 44:230-232.
14. D. Grunberger, K. Frenkel, Inhibition of Cataract Formation, Diseases Resulting from Oxidative Stress, and HIV Replication by Caffeic Acid Esters, United States Patent, 5591,773, 1997.
15. Frenkel K., Wei H., Bhimani R., Ye J., Zadunaisky J.A., Huang M.T., Ferraro T., Conney A.H., Grunberger D. Inhibition of tumor promoter mediated processes in mouse skin and bovine lens by caffeic acid phenethyl ester. Cancer Res. 1993, 53:1255-1261.
16. Huang M.T., Ma W., Yen P., Xie J.G., Han J., Frenkel K., Grunberger D., Conney A.H. Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells. Carcinogenesis 1996, 17:761-765.
17. Son S., Lewis B.A. Free radical scavenging and antioxidative activity of caffeic acid amide and ester analogues: structure-activity relationship. J. Agric. Food Chem. 2002, 50:468-472.
18. Koltuksuz U., Mutus H.M., Kutlu R., Ozyurt H., Cetin S., Karaman A., Gürbüz N., Akyol O., Aydin N.E. Effects of caffeic acid phenethyl ester and epidermal growth factor on the development of caustic esophageal stricture in rats. J. Pediatr. Surg. 2001, 36:1504-1509.
19. Michaluart P., Masferrer J.L., Carothers A.M., Subbaramaiah K., Zweifel B.S., Koboldt C., Mestre J.R., Grunberger D., Sacks P.G., Tanabe T., Dannenberg A.J. Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Cancer Res. 1999, 59:2347-2352.
20. Borrelli F., Izzo A.A., Di Carlo G., Maffia P., Russo A., Maiello F.M., Capasso F., Mascolo N. Effect of a propolis extract and caffeic acid phenethyl ester on formation of aberrant crypt foci and tumors in the rat colon. Fitoterapia 2002, 73:S38-S43.
21. Natarajan K., Singh S., Burke T.R., Grunberger D., Aggarwal B.B. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB. Proc. Natl. Acad. Sci. USA 1996, 93:9090-9095.
22. Watabe M., Hishikawa K., Takayanagi A., Shimizu N., Nakaki T. Caffeic acid phenethyl ester induces apoptosis by inhibition of NF-κB and activation of Fas in human breast cancer MCF-7 cells. J. Biol. Chem. 2004, 279:6017-6026.
23. Fitzpatrick L.R., Wang J., Le T. Caffeic acid phenethyl ester, an inhibitor of nuclear factor-κB, attenuates bacterial peptidoglycan polysaccharide-induced colitis in rats. J. Pharmacol. Exp. Ther. 2001, 299:915-920.
24. Chen Y.J., Shiao M.S., Hsu M.L., Tsai T.H., Wang S.Y. Effect of caffeic acid phenethyl ester, an antioxidant from propolis, on inducing apoptosis in human leukemic HL-60 cells. J. Agric. Food Chem. 2001, 49(11):5615-5619.
25. Kimura Y., Okuda H., Okuda T., Hatano T., Agata I., Arichi S. Studies on the activities of tannins and related compounds from medicinal plants and drugs. VII. Effects of extracts of leaves of Artemisia species, and caffeic acid and chlorogenic acid on lipid metabolic injury in rats fed peroxidized oil. Chem. Pharm. Bull. (Tokyo) 1985, 33:2028-2034.
26. Laranjinha J., Vieira O., Madeira V., Almeida L. Two related phenolic antioxidants with opposite effects on vitamin E content in low density lipoproteins oxidized by ferrylmyoglobin: consumption vs regeneration. Arch. Biochem. Biophys. 1995, 323:373-381.
27. Xiang D., Wang D., He Y., Xie J., Zhong Z., Li Z., Xie J. Caffeic acid phenethyl ester induces growth arrest and apoptosis of colon cancer cells via the beta-catenin/T-cell factor signaling. Anti Cancer Drugs 2006, 17(7):753-762.
28. Chen M.F., Wu C.T., Chen Y.J., Keng P.C., Chen W.C. Cell killing and radiosensitization by caffeic acid phenethyl ester (CAPE) in lung cancer cells. J. Radiat. Res. 2004, 45(2):253-260.
29. S.K. Kudugunti, N.M. Vad, E. Ekogbo, M.Y. Moridani, Efficacy of caffeic acid phenethyl ester (CAPE) in skin B16-F0 melanoma tumor bearing C57BL/6 mice, Invest. New Drugs 29 (2011) 52-62. doi:10.1007/s10637-009-9334-5.
30. Kuo H.S., Kuo W.H., Lee Y.J., Lin W.L., Chou F.P., Tseng T.H. Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo. Cancer Lett. 2006, 234(2):199-208.
31. Chen M.J., Chang W.H., Lin C.C., Liu C.Y., Wang T.E., Chu C.H., Shih S.C., Chen Y.J. Caffeic acid phenethyl ester induces apoptosis of human pancreatic cancer cells involving caspase and mitochondrial dysfunction. Pancreatology 2008, 8(6):566-576.
32. Wu C.S., Chen M.F., Lee I.L., Tung S.Y. Predictive role of nuclear factor-kappa B activity in gastric cancer: a promising adjuvant approach with caffeic acid phenethyl ester. J. Clin. Gastroenterol. 2007, 41(10):871-873.
33. Onori P., DeMorrow S., Gaudio E., Franchitto A., Mancinelli R., Venter J., Kopriva S., Ueno Y., Alvaro D., Savage J., Alpini G., Francis H. Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappa B and induction of apoptosis. Int. J. Cancer 2009, 125(3):565-576.
34. Lee K.W., Kang N.J., Kim J.H., Lee K.M., Lee D.E., Hur H.J., Lee H.J. Caffeic acid phenethyl ester inhibits invasion and expression of matrix metalloproteinase in SK-Hep1 human hepatocellular carcinoma cells by targeting nuclear factor kappa B. Genes Nutr. 2008, 2(4):319-322.
35. J. Wu, L. Horton, M. Bosland, J. Karkoszka, K. Frenkel, Caffeic acid phenethyl ester (CAPE) as a preventive agent in a preclinical model of breast cancer, in: Proceedings of the American Association for Cancer Research, 2007, Abstract #4202.
36. J. Wu, U. Bukkapatnam, J. Eckard, K. Frenkel, Caffeic acid phenethyl ester (CAPE, a product of propolis) as an inhibitor of human breast cancer growth in a pre-clinical study and its effects on factors involved in cell cycle, angiogenesis, and drug resistance, in: Proceedings of the American Association for Cancer Research, 2008, Abstract #5710.
37. J. Wu, C. Omene, J. Smith, K. Frenkel, Inhibition of breast cancer stem cells (CSC) self-renewal and growth by CAPE, a product of propolis, in: Proceedings of the American Association for Cancer Research, 2010, Abstract #3555.
38. J. Wu, C. Omene, J. Karkoszka, C.B. Klein, J. Smith, K. Frenkel, CAPE, a honeybee product, inhibits growth of human breast cancer xenografts by oral and topical routes and suppresses self-renewal of breast cancer stem cells, in: Proceedings of the American Association for Cancer Research, 2009, Abstract #2345.
39. C. Omene, J. Mu, K. Frenkel, Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells, Invest. New Drugs (2011), doi:10.1007/s10637-011-9667-8.
40. Ahn M.R., Kunimasa K., Kumazawa S., Nakayama T., Kaji K., Uto Y., Hori H., Nagasawa H., Ohta T. Correlation between anti-angiogenic activity and antioxidant activity of various components from propolis. Mol. Nutr. Food Res. 2009, 53(5):643-651.
41. Liao H.F., Chen Y.Y., Liu J.J., Hsu M.L., Shieh H.J., Liao H.J., Shieh C.J., Shiao M.S., Chen Y.J. Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumor invasion and metastasis. J. Agric. Food Chem. 2003, 51:7907-7912.
42. Foley J., Nickerson N.K., Nam S., Allen K.T., Gilmore J.L., Nephew K.P., Riese D.J. EGFR signaling in breast cancer: bad to the bone. Semin. Cell Dev. Biol. 2010, 10.1016/j.semcdb.2010.08.009.
43. Carey L.A. Directed therapy of subtypes of triple-negative breast cancer. Oncologist 2010, 15(Suppl. 5):49-56.
44. Conlin A.K., Seidman A.D. Taxanes in breast cancer: an update. Curr. Oncol. Rep. 2007, 9:22-30.
45. Jones S.E. Metastatic breast cancer: the treatment challenge. Clin. Breast Cancer 2008, 8:224-233.
46. Schwartz J., Wong S.T. Novel combinations for treating metastatic breast cancer: improving the odds, introduction. Am. J. Health Syst. Pharm. 2009, 66(23 Suppl. 6):S1-S2.
47. Wong S.T., Goodin S. Overcoming drug resistance in patients with metastatic breast cancer. Pharmacotherapy 2009, 29(8):954-965.
48. Longley D.B., Johnston P.G. Molecular mechanisms of drug resistance. J. Pathol. 2005, 205:275-292.
49. Song Y.S., Park E.H., Jung K.J., Jin C. Inhibition of angiogenesis by propolis. Arch. Pharm. Res. 2002, 25(4):500-504.
50. Biswas D., Iglehart J.D. Linkage between EGFR family receptors and nuclear factor kappa B (NF-κB) signaling in breast cancer. J. Cell. Physiol. 2006, 209:645-652.
51. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 1971, 285:1182-1186.
52. Naumov G.N., Akslen L.A., Folkman J. Role of angiogenesis in human tumor dormancy. Cell Cycle 2006, 5:1779-1787.
53. Zhang X., Jin B., Huang C. The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. Curr. Cancer Drug Targets 2007, 7:305-316.
54. Lu T., Stark G.R. Cytokine overexpression and constitutive NF-κB in cancer. Cell Cycle 2004, 3:1114-1117.
55. Kucharczak J., Simmons M.J., Fan Y., Gelinas C. To be, or not to be: NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene 2003, 22:8961-8982.
56. Weisz L., Damalas A., Liontos M., Karakaidos P., Fontemaggi G., Maor-Aloni R., Kalis M., Levrero M., Strano S., Gorgoulis V.G., Rotter V., Blandino G., Oren M. Mutant p53 enhances nuclear factor κB activation by tumor necrosis factor a in cancer cells. Cancer Res. 2007, 67:2396-2401.
57. Fabre C., Grosjean J., Tailler M., Boehrer S., Ades L., Perfettini J.L., de Botton S., Fenaux P., Kroemer G. A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NF-κB inhibition in malignant myeloblasts. Cell Cycle 2008, 7:2139-2145.
58. Beg A.A., Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996, 274:782-784.
59. Escarcega R.O., Fuentes-Alexandro S., Garcia-Carrasco M., Gatica A., Zamora A. The transcription factor nuclear factor-κB and cancer. Clin. Oncol. (R. Coll. Radiol.) 2007, 19:154-161.
60. Pazdur R., Wagman L.D., Camphausen K.A., Hoskins W.J. Cancer Management: A Multidisciplinary Approach, Medical, Surgical and Radiation Oncology 2010, UBM Medica. 13th ed.
61. Fagan D.H., Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13(4):423-429.
62. Freiss G., Rochefort H., Vignon F. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity. Biochem. Biophys. Res. Commun. 1990, 173:919-926.
63. Wakeling A.E., Newboult E., Peters S.W. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. J. Mol. Endocrinol. 1989, 2:225-234.
64. Litzenburger B.C., Creighton C.J., Tsimelzon A., Chan B.T., Hilsenbeck S.G., Wang T., Carboni J.M., Gottardis M.M., Huang F., Chang J.C., Lewis M.T., Rimawi M.F., Lee A.V. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin. Cancer Res. 2010, 10.1158/1078-0432.CCR-10-1903.